Interestingly in our study, higher Chemerin plasma values at disease onset, but not the overweight-obesity status nor higher PEDF plasma values, was associated with remission achievement, identifying Chemerin as a biomarker of metaflammation and as a modifiable risk factor associated with RA treatment response (16, 39). Here, RARRES2 is linked to obesity due to melanocortin 4 receptor deficiency.